课题基金 / 基金详情

ANTIGEN MARKERS IN DIAGNOSIS OF PROSTATE CANCER

ANTIGEN MARKERS IN DIAGNOSIS OF PROSTATE CANCER
诊断前列腺癌的抗原标记
批准号:
3164177
负责人:
Tsann Ming Chu
金额:
$10.01万
依托单位国家:
美国
项目类别:
财政年份:
1976
资助国家:
美国
项目状态:
已结题
起止时间:
1976-12-01 至 1986-05-31

项目摘要

项目成果

Tsann Ming Chu的其他基金

相似基金

相关文献

中文摘要
翻译
这项建议的目的是继续我们对抗原标志物的研究, 可以用于检测前列腺癌。 一个新的,具体的, 酸性磷酸酶的灵敏固相免疫荧光测定法是 评价其在前列腺癌早期诊断中的潜在价值。 一 前列腺特异性抗原已被纯化至同质。 异种抗血清具有 针对前列腺抗原和抗血清的特异性 将被确定。 初步数据表明,该抗原可能具有潜在的 用于鉴别前列腺癌患者。 一种新的灵敏的免疫测定法, 如放射免疫测定法或酶免疫测定法,将被开发和评估。 在 此外,前列腺肿瘤特异性抗原已被证明, 在非人类灵长类动物(狒狒)中产生了针对它的抗体。 孤立, 该前列腺癌抗原的纯化和表征将是 执行。 此外,前列腺酸性磷酸酶结合球蛋白已被发现。 通过使用纯化的亲和色谱法从正常人血清中分离 前列腺酸性磷酸酶 其在前列腺的潜在临床应用 将研究肿瘤放射定位和免疫治疗。 最后通过一个 用于测量血清核糖核酸酶的免疫测定法正在被开发, 已经实现了两种前列腺核糖核酸酶的纯化。
英文摘要
The objective of this proposal is to continue our study on antigen markers which may be useful in the detection of prostate cancer. A new, specific and sensitive solid-phase immunofluorescence assay for acid phosphatase is to be evaluated for its potential value in the early diagnosis of prostate cancer. A prostate-specific antigen has been purified to homogeneity. Xenoantisera have been raised against the prostate antigen and the specificity of the antisera will be determined. Initial data indicate that this antigen may be of potential use in identifying prostate cancer patients. A new sensitive immunoassay, such as radioimmunoassay or enzyme immunoassay, will be developed and evaluated. In addition, a prostate tumor-specific antigen has been demonstrated and antiserum against it has been produced in non-human primates (baboon). Isolation, purification and characterization of this prostate cancer antigen will be performed. Furthermore, a prostate acid phosphatase-binding globulin has been isolated from normal human serum by affinity chromatography using purified prostatic acid phosphatase. Its potential clinical application in prostate tumor radiolocalization and immunotherapy will be studied. Finally, an immunoassay for measurement of serum ribonuclease is being developed, as purification of two prostatic ribonucleases has been achieved.
期刊论文(30)
专著(0)
科研奖励(0)
会议论文
Use of human prostate-specific antigen in monitoring prostate cancer.
使用人类前列腺特异性抗原监测前列腺癌。
DOI: --
发表时间: 1981
期刊: Cancer research
影响因子: 11.2
作者: [Kuriyama,M, Wang,MC, Lee,CI, Papsidero,LD, Killian,CS, Inaji,H, Slack,NH, Nishiura,T, Murphy,GP, Chu,TM]
通讯作者: Chu,TM
Quantitative counterimmunoelectrophoresis assay for prostatic acid phosphatase.
前列腺酸性磷酸酶的定量反免疫电泳测定。
DOI: --
发表时间: 1980
期刊: Investigative urology
影响因子: --
作者: [Killian,CS, Vargas,FP, Lee,CL, Wang,MC, Murphy,GP, Chu,TM]
通讯作者: Chu,TM
Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer.
前列腺特异性抗原对于监测 B2 至 D1 期前列腺癌患者的预后重要性。
DOI: --
发表时间: 1985
期刊: Cancer research
影响因子: 11.2
作者: [Killian,CS, Yang,N, Emrich,LJ, Vargas,FP, Kuriyama,M, Wang,MC, Slack,NH, Papsidero,LD, Murphy,GP, Chu,TM]
通讯作者: Chu,TM
Circulating antibody to prostate antigen in patients with prostate cancer.
前列腺癌患者体内循环的前列腺抗原抗体。
DOI: --
发表时间: 1984
期刊: Transplantation proceedings
影响因子: 0.9
作者: [Chu,TM, Kuriyama,M, Johnson,E, Papsidero,LD, Killian,CS, Murphy,GP, Wang,MC]
通讯作者: Wang,MC
24
    TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
    • 批准号:
      3175435
    • 项目类别:
    • 资助金额:
      $11.26万
    • 财政年份:
      1984
    • 负责人:
      Tsann Ming Chu
    • 依托单位:
    TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
    • 批准号:
      3175437
    • 项目类别:
    • 资助金额:
      $10.08万
    • 财政年份:
      1984
    • 负责人:
      Tsann Ming Chu
    • 依托单位:
    TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
    • 批准号:
      3175434
    • 项目类别:
    • 资助金额:
      $10.98万
    • 财政年份:
      1984
    • 负责人:
      Tsann Ming Chu
    • 依托单位:
    TARGETING AND THERAPY OF TUMORS WITH MONOCLONAL ANTIBODY
    • 批准号:
      3175432
    • 项目类别:
    • 资助金额:
      $21.41万
    • 财政年份:
      1984
    • 负责人:
      Tsann Ming Chu
    • 依托单位:
    海外基金